Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy.

Autor: Ramos Perez, Jorge M.1 (AUTHOR), Patel, Keyur P.2 (AUTHOR), Loghavi, Sanam2 (AUTHOR), Garcia-Manero, Guillermo1 (AUTHOR), Borthakur, Gautam1 (AUTHOR), Jabbour, Elias1 (AUTHOR), Wierda, William1 (AUTHOR), Pierce, Sherry1 (AUTHOR), Brandt, Mark1 (AUTHOR), Kornblau, Steven1 (AUTHOR), Kadia, Tapan1 (AUTHOR), Daver, Naval1 (AUTHOR), DiNardo, Courtney D.1 (AUTHOR), Jain, Nitin1 (AUTHOR), Yilmaz, Musa1 (AUTHOR), Short, Nicholas1 (AUTHOR), Verstovsek, Srdan1 (AUTHOR), Ferrajoli, Alessandra1 (AUTHOR), Andreeff, Michael1 (AUTHOR), Konopleva, Marina1 (AUTHOR)
Zdroj: Leukemia & Lymphoma. Mar2022, Vol. 63 Issue 3, p672-675. 4p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje